- Home
- TLPH vs TXMD Comparison
TLPH vs TXMD Comparison
Compare TLPH & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLPH
- TXMD
- Stock Information
- Founded
- TLPH 2005
- TXMD 2008
- Country
- TLPH United States
- TXMD United States
- Employees
- TLPH N/A
- TXMD N/A
- Industry
- TLPH Biotechnology: Pharmaceutical Preparations
- TXMD Biotechnology: Pharmaceutical Preparations
- Sector
- TLPH Health Care
- TXMD Health Care
- Exchange
- TLPH Nasdaq
- TXMD Nasdaq
- Market Cap
- TLPH 12.7M
- TXMD 12.8M
- IPO Year
- TLPH 2011
- TXMD N/A
- Fundamental
- Price
- TLPH $0.51
- TXMD $1.09
- Analyst Decision
- TLPH Strong Buy
- TXMD
- Analyst Count
- TLPH 2
- TXMD 0
- Target Price
- TLPH $4.50
- TXMD N/A
- AVG Volume (30 Days)
- TLPH 108.9K
- TXMD 21.5K
- Earning Date
- TLPH 11-13-2024
- TXMD 11-12-2024
- Dividend Yield
- TLPH N/A
- TXMD N/A
- EPS Growth
- TLPH N/A
- TXMD N/A
- EPS
- TLPH N/A
- TXMD N/A
- Revenue
- TLPH $281,000.00
- TXMD $1,596,000.00
- Revenue This Year
- TLPH N/A
- TXMD $605.07
- Revenue Next Year
- TLPH N/A
- TXMD $1.11
- P/E Ratio
- TLPH N/A
- TXMD N/A
- Revenue Growth
- TLPH N/A
- TXMD N/A
- 52 Week Low
- TLPH $0.50
- TXMD $1.05
- 52 Week High
- TLPH $1.61
- TXMD $2.75
- Technical
- Relative Strength Index (RSI)
- TLPH 29.73
- TXMD 25.26
- Support Level
- TLPH $0.64
- TXMD $1.06
- Resistance Level
- TLPH $0.69
- TXMD $1.15
- Average True Range (ATR)
- TLPH 0.06
- TXMD 0.07
- MACD
- TLPH -0.01
- TXMD -0.01
- Stochastic Oscillator
- TLPH 1.54
- TXMD 16.00
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
About TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.